US equities |
SPCX $174.44 ▲+1.96% NVDA $242.13 ▲+1.35% MU $1,073.28 ▲+0.88% MRVL $296.87 ▲+9.45% AMD $643.60 ▲+1.88% SNDK $1,689.39 ▼-0.87% TSLA $379.93 ▲+0.32% META $739.09 ▼-0.38%
FinancialContent

Absci Corporation - Common Stock (NQ:ABSI)

11.02 -0.51 (-4.42%)
Delayed Quote Updated: 10:05 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci (ABSI) Q2 2026 Earnings Call Transcript ↗
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal. 
Via The Motley Fool
Topics Earnings
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
Absci Corp (NASDAQ:ABSI) Plunges on 86% Q1 Revenue Miss Despite Clinical Advances ↗
Via Chartmill
News headline image
Absci Q2 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
From Absci Corporation
Via GlobeNewswire
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday. ↗
Via Chartmill
News headline image
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
From Absci Corporation
Via GlobeNewswire
News headline image
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 ↗
A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci (ABSI) Q1 2026 Earnings Call Transcript ↗
Absci (ABSI) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
From Absci Corporation
Via GlobeNewswire
News headline image
Absci (ABSI) Q4 2025 Earnings Call Transcript ↗
Absci (ABSI) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >